Hashimoto's Thyroiditis Pathology and Risk for Thyroid Cancer
Abstract
Background: Hashimoto's thyroiditis (HT) has been found to coexist with differentiated thyroid cancer (DTC) in surgical specimens, but an association between the two conditions has been discounted by the medical literature. Therefore, we performed this study to determine any potential relationship between HT and the risk of developing DTC.
Methods: We collected data for thyrotropin (TSH), thyroxine (T4), thyroid peroxidase antibody (TPO-Ab) titers, surgical pathology, and weight-based levothyroxine (LT4) replacement dose for patients who were referred for thyroid surgery. Patients with HT at final pathology were studied further. To estimate thyroid function, patients with preoperative hypothyroid HT (Hypo-HT) were divided into three equal groups based on their LT4 replacement: LT4-Low (<0.90 μg/kg), LT4-Mid (0.90–1.43 μg/kg), and LT4-High (>1.43 μg/kg). A group of preoperatively euthyroid (Euth-HT) patients but with HT by pathology was also studied. All subjects were also grouped based on their TPO-Ab titer in TPO-high (titer >1:1000) or TPO-low/negative (titer <1:1000 or undetectable) groups. The relationship of HT and DTC was studied extensively.
Results: Of 2811 subjects, 582 had HT on surgical pathology, 365 of whom were Euth-HT preoperatively. DTC was present in 47.9% of the Euth-HT, in 59.7% of LT4-Low, 29.8% of LT4-Mid, and 27.9% of LT4-High groups. The relative risk (RR) for DTC was significantly elevated for the Euth-HT and LT4-Low groups (p<0.001), but not for the LT4-Mid or LT4-High replacement dose groups. TPO-low/negative status conferred an increased RR in the Euth-HT and LT4-Low replacement dose groups (p<0.001 both), while TPO-high status decreased it in Euth-HT group (p<0.05) and made it nonsignificant in the LT4-Low group.
Conclusions: HT pathology increases the risk for DTC only in euthyroid subjects and those with partially functional thyroid glands (LT4-Low) but not in fully hypothyroid HT (LT4-Mid and LT4-High). High TPO-Ab titers appear to protect against DTC in patients with HT.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Li N, Du XL, Reitzel LR, Xu L, Sturgis EM 2013 Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the Surveillance, Epidemiology, and End Results registry, 1980–2008. Thyroid 23:103–110.
2.
Chen H, Schneider D, Mazeh H, Jaume JC, Lubner S 2013 Endocrine Cancer. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG (eds) Abeloff's Clinical Oncology, 5th edition. Churchill Livingstone Elsevier, Philadelphia, PA, pp. 1112–1142.
3.
Braverman LE 1994 Iodine and the thyroid: 33 years of study. Thyroid 4:351–356.
4.
Virchow R 1956 Standpoints in Scientific Medicine, 1877. Bull Hist Med 30:537–543.
5.
Balkwill F, Mantovani A 2001 Inflammation and cancer: back to Virchow? Lancet 357:539–545.
6.
Franks AL, Slansky JE 2012 Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 32:1119–1136.
7.
Dailey ME, Lindsay S, Skahen R 1955 Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 70:291–297.
8.
Holm LE, Blomgren H, Lowhagen T 1985 Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 312:601–604.
9.
Cipolla C, Sandonato L, Graceffa G, Fricano S, Torcivia A, Vieni S, Latteri S, Latteri MA 2005 Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg 71:874–878.
10.
Dvorkin S, Robenshtok E, Hirsch D, Strenov Y, Shimon I, Benbassat CA 2013 Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting hashimotos thyroiditis. J Clin Endocrinol Metab 98:2409–2414.
11.
Eisenberg BL, Hensley SD 1989 Thyroid cancer with coexistent Hashimoto's thyroiditis. Clinical assessment and management. Arch Surg 124:1045–1047.
12.
Fiore E, Rago T, Latrofa F, Provenzale MA, Piaggi P, Delitala A, Scutari M, Basolo F, Di Coscio G, Grasso L, Pinchera A, Vitti P 2011 Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer 18:429–437.
13.
Fiore E, Rago T, Scutari M, Ugolini C, Proietti A, Di Coscio G, Provenzale MA, Berti P, Grasso L, Mariotti S, Pinchera A, Vitti P 2009 Papillary thyroid cancer, although strongly associated with lymphocytic infiltration on histology, is only weakly predicted by serum thyroid auto-antibodies in patients with nodular thyroid diseases. J Endocrinol Invest 32:344–351.
14.
Jankovic B, Le KT, Hershman JM 2013 Clinical Review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 98:474–482.
15.
Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, Evers BM 2007 Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 204:764–773.
16.
Ott RA, McCall AR, McHenry C, Jarosz H, Armin A, Lawrence AM, Paloyan E 1987 The incidence of thyroid carcinoma in Hashimoto's thyroiditis. Am Surg 53:442–445.
17.
Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H 2008 Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 150:49–52.
18.
Zhang L, Li H, Ji QH, Zhu YX, Wang ZY, Wang Y, Huang CP, Shen Q, Li DS, Wu Y 2012 The clinical features of papillary thyroid cancer in Hashimoto's thyroiditis patients from an area with a high prevalence of Hashimoto's disease. BMC Cancer 12:610.
19.
Okayasu I, Fujiwara M, Hara Y, Tanaka Y, Rose NR 1995 Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans. Cancer 76:2312–2318.
20.
Rago T, Di Coscio G, Ugolini C, Scutari M, Basolo F, Latrofa F, Romani R, Berti P, Grasso L, Braverman LE, Pinchera A, Vitti P 2007 Clinical features of thyroid autoimmunity are associated with thyroiditis on histology and are not predictive of malignancy in 570 patients with indeterminate nodules on cytology who had a thyroidectomy. Clin Endocrinol 67:363–369.
21.
Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC, Chen H 2009 Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol 71:434–439.
22.
Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H 2008 Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metabl 93:809–814.
23.
Song Y, Driessens N, Costa M, De Deken X, Detours V, Corvilain B, Maenhaut C, Miot F, Van Sande J, Many MC, Dumont JE 2007 Roles of hydrogen peroxide in thyroid physiology and disease. J Clin Endocrinol Metab 92:3764–3773.
24.
Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P, Pilotti S, Cassinelli G, Bressan P, Fugazzola L, Mantovani A, Pierotti MA 2005 Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102:14825–14830.
25.
Nose F, Ichikawa T, Fujiwara M, Okayasu I 2002 Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase. Am J Clin Pathol 117:546–551.
26.
Schreiber RD, Old LJ, Smyth MJ 2011 Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565–1570.
27.
Imam S, Paparodis R, Sharma D, Jaume JC 2014 Lynphocytic profiling in thyroid cancer provides clues for failure of tumor immunity. Endocr Relat Cancer 21:505–516.
28.
Kaufman HL, Wolchok JD 2006 Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. J Clin Oncol 24:2230–2232.
Information & Authors
Information
Published In
Copyright
Copyright 2014, Mary Ann Liebert, Inc.
History
Published online: 3 July 2014
Published in print: July 2014
Published ahead of print: 5 June 2014
Published ahead of production: 7 April 2014
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.